Literature DB >> 10848217

The optic nerve head in normal-tension glaucoma.

G Tomita1.   

Abstract

There is controversy over the definition, appearance, and characteristics of the optic nerve head in normal-tension glaucoma (NTG). Optic disk size is greater in eyes with NTG than in those with primary open-angle glaucoma. However, in an intraindividual bilateral comparison, the eye with the larger optic disk showed neither more marked nor less pronounced glaucomatous optic nerve damage. Optic disk hemorrhage and peripapillary atrophy have been reported to be more frequent in patients with NTG. Nonuse of calcium channel blockers, peripapillary atrophy, and disk hemorrhage were statistically significantly associated with visual field loss progression in NTG. However, there is a possibility that a high IOP may stop disk hemorrhage relatively early. Histopathologic optic nerve head changes correlated with the clinical appearance of the optic nerve head, which is comparable in NTG and primary open-angle glaucoma. However, as novel findings, serum antibodies to retinal proteins and retinal immunoglobulin deposition in the ganglion cells were observed, and the level of serum autoantibodies to optic nerve head glycosaminoglycans was higher in patients with NTG than in patients with primary open-angle glaucoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848217     DOI: 10.1097/00055735-200004000-00009

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  13 in total

1.  Coincidence of normal tension glaucoma, progressive sensorineural hearing loss, and elevated antiphosphatidylserine antibodies.

Authors:  S Kremmer; E Kreuzfelder; E Bachor; K Jahnke; J M Selbach; S Seidahmadi
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

Review 2.  Neurodegeneration in glaucoma: progression and calcium-dependent intracellular mechanisms.

Authors:  S D Crish; D J Calkins
Journal:  Neuroscience       Date:  2010-12-25       Impact factor: 3.590

3.  Clinicopathologic correlation of disc and peripapillary region using SD-OCT.

Authors:  Eric J Sigler; Kristy G Mascarenhas; James C Tsai; Nils A Loewen
Journal:  Optom Vis Sci       Date:  2013-01       Impact factor: 1.973

4.  Antiphosphatidylserine antibodies are elevated in normal tension glaucoma.

Authors:  S Kremmer; E Kreuzfelder; R Klein; N Bontke; K B Henneberg-Quester; K P Steuhl; H Grosse-Wilde
Journal:  Clin Exp Immunol       Date:  2001-08       Impact factor: 4.330

5.  Clinical features and glaucoma according to optic disc size in a South Korean population: the Namil study.

Authors:  Na Hee Kang; Roo Min Jun; Kyu-Ryong Choi
Journal:  Jpn J Ophthalmol       Date:  2014-01-28       Impact factor: 2.447

Review 6.  Glaucoma: an extension of various chronic neurodegenerative disorders.

Authors:  Vishal Jindal
Journal:  Mol Neurobiol       Date:  2013-02-10       Impact factor: 5.590

7.  Sensitized heat shock protein 27 induces retinal ganglion cells apoptosis in rat glaucoma model.

Authors:  Wei Zhao; Le Dai; Xiao-Ting Xi; Qian-Bo Chen; Mei-Xia An; Yan Li
Journal:  Int J Ophthalmol       Date:  2020-04-18       Impact factor: 1.779

Review 8.  From mechanosensitivity to inflammatory responses: new players in the pathology of glaucoma.

Authors:  David Križaj; Daniel A Ryskamp; Ning Tian; Gülgün Tezel; Claire H Mitchell; Vladlen Z Slepak; Valery I Shestopalov
Journal:  Curr Eye Res       Date:  2013-10-21       Impact factor: 2.424

Review 9.  Optic disk size and glaucoma.

Authors:  Esther M Hoffmann; Linda M Zangwill; Jonathan G Crowston; Robert N Weinreb
Journal:  Surv Ophthalmol       Date:  2007 Jan-Feb       Impact factor: 6.197

10.  Induction of amyloid-β(1-42) in the retina and optic nerve head of chronic ocular hypertensive monkeys.

Authors:  Yasushi Ito; Masamitsu Shimazawa; Kazuhiro Tsuruma; Chihiro Mayama; Kiyoshi Ishii; Hirotaka Onoe; Makoto Aihara; Makoto Araie; Hideaki Hara
Journal:  Mol Vis       Date:  2012-10-29       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.